GBGB1710879.6A
GB201710879D0
(en)
|
2017-07-06 |
2017-07-06 |
Methods and compounds for tumour-specific cell depletion
|
US16/494,962
US11879014B2
(en)
|
2017-03-17 |
2018-03-03 |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
EP18711313.9A
EP3596123B1
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
CN201880018976.8A
CN110869388A
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-CD 25 for tumor-specific cell depletion
|
KR1020197030283A
KR20190130137A
(en)
|
2017-03-17 |
2018-03-13 |
FC-optimized anti-CD25 for tumor specific cell depletion
|
PCT/EP2018/056312
WO2018167104A1
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
PE2019001847A
PE20191812A1
(en)
|
2017-03-17 |
2018-03-13 |
COMPOUNDS AND METHODS FOR SPECIFIC CELL TUMOR REDUCTION
|
MX2019010974A
MX2019010974A
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion.
|
SG11201908578Y
SG11201908578YA
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
FIEP18711313.9T
FI3596123T3
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
AU2018233976A
AU2018233976A1
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-CD25 for tumour specific cell depletion
|
RS20240376A
RS65351B1
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
LTEPPCT/EP2018/056312T
LT3596123T
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
JP2019550705A
JP2020514363A
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-CD25 for tumor-specific cell depletion
|
BR112019017017A
BR112019017017A2
(en)
|
2017-03-17 |
2018-03-13 |
method of treating a human individual who has cancer, anti-cd25 antibody, use of an anti-cd25 antibody, combination of an anti-cd25 antibody, kit for use in the treatment of cancer, pharmaceutical composition, combination, bispecific antibody, method of cancer treatment, and method of depleting regulatory t cells in an individual
|
CA3056506A
CA3056506A1
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
CR20190477A
CR20190477A
(en)
|
2017-03-17 |
2018-03-13 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
DK18711313.9T
DK3596123T3
(en)
|
2017-03-17 |
2018-03-13 |
FC-optimized anti-CD25 for tumor-specific cell depletion
|
CN201880045359.7A
CN111094346A
(en)
|
2017-07-06 |
2018-07-06 |
Compounds and methods for tumor-specific cell depletion
|
US16/628,713
US20200283535A1
(en)
|
2017-07-06 |
2018-07-06 |
Compounds and methods for tumour-specific cell depletion
|
JP2019572678A
JP7225135B2
(en)
|
2017-07-06 |
2018-07-06 |
Compounds and methods for tumor-specific cell depletion
|
EP18742582.2A
EP3649153A1
(en)
|
2017-07-06 |
2018-07-06 |
Compounds and methods for tumour-specific cell depletion
|
PCT/GB2018/051923
WO2019008386A1
(en)
|
2017-07-06 |
2018-07-06 |
Compounds and methods for tumour-specific cell depletion
|
IL26908119A
IL269081A
(en)
|
2017-03-17 |
2019-09-02 |
Fc-optimized anti-cd25 for tumour specific cell depletion
|
CL2019002624A
CL2019002624A1
(en)
|
2017-03-17 |
2019-09-13 |
Compounds and methods for specific cell reduction.
|
JP2024009215A
JP2024050684A
(en)
|
2017-03-17 |
2024-01-25 |
Fc-optimized anti-CD25 for tumor-specific cell depletion
|